Crossmark

SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials

Crossref DOI link: https://doi.org/10.1007/s11892-018-1038-9

Published Online: 2018-07-11

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jia, Xiaoming

Mehta, Paras B.

Ye, Yumei

Alam, Mahboob

Birnbaum, Yochai

Bajaj, Mandeep
License Information

Text and Data Mining valid from 2018-07-11
More Information

Article History

First Online: 11 July 2018

Compliance with Ethical Standards

:

: Xiaoming Jia, Paras B. Mehta, and Mahboob Alam declare that they have no conflict of interest.Yumei Ye reports grants from AstraZeneca and Boehringer-Ingelheim.Yochai Birnbaum reports grants from AstraZeneca and Boehringer-Ingelheim.Mandeep Bajaj reports grants from Amylin, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Sanofi-Aventis, and Novo Nordisk.

: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).